Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in:

03.08.2020 | Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Addressing Sphincter Dysfunction in the Female with Neurogenic Lower Urinary Tract Dysfunction

verfasst von: Javier E. Santiago, Anne P. Cameron, Roberto A. Navarrete

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Neurogenic sphincter dysfunction in females will be discussed with reference to both foundational and contemporary research with an emphasis on tools for urologic management. The article will focus on both conservative and surgical options for patients broadly characterized with underactive or overactive sphincter dysfunction.

Recent Findings

There is limited recently published prospective data to guide management; however, there exist several insightful retrospective studies to guide practice.

Summary

The bulk of literature for the management of sphincter dysfunction for this complex patient population remains retrospective, and choice of intervention continues to rely upon individual patient characteristics and goals of care to maintain safety and quality of life.
Literatur
1.
Griffiths D, Derbyshire S, et al. Brain control of normal and overactive bladder. J Urol. 2005;174:1862–7.PubMed
2.
Wein AJ, Kavoussi LR, Partin AW, Peters CA (2016) Physiology and pharmacology of the bladder and urethra. In: Campbell-Walsh Urology. Eleventh edition., Elsevier.
3.
4.
DeLancey JO. Anatomy and physiology of urinary continence. Clin Obstet Gynecol. 1990;33(2):298–307.PubMed
5.
Gajewski JB, Schurch B, Hamid R, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn. 2017:1–10.
6.
Wein AJ, Kavoussi LR, Partin AW, Peters CA. Pathophysiology and classification of lower urinary tract dysfunction: overview. In: Campbell-Walsh Urology. Eleventh edition., Elsevier, 2016.
7.
McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126(2):205–9.PubMed
8.
Wein AJ, Kavoussi LR, Partin AW, Peters CA. Neuromuscular dysfunction of the lower urinary tract. Campbell-Walsh Urology. Eleventh edition., Elsevier: In; 2016.
9.
Blaivas JG, Sinha HP, Zayed AA, et al. Detrusor–external sphincter dyssynergia. J Urol. 1981;125:542–4.PubMed
10.
Stoffel JT. Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. Transl Androl Urol. 2016;5(1):127–35.PubMedPubMedCentral
11.
Wein AJ, Kavoussi LR, Partin AW, Peters CA. Urodynamic and video-urodynamic evaluation of the lower urinary tract. In: Campbell-Walsh Urology. Eleventh edition., Elsevier, 2016.
12.
Grape HH, Dedering A, Jonasson AF. Retest reliability of surface electromyography on the pelvic floor muscles. Neurourol Urodyn. 2013;32:215–23.
13.
Palma JA, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. Auton Neurosci Basic Clin. 2018;211:15–25.
14.
Jellinger KA. Multiple system atrophy: an oligodendroglioneural synucleinopathy. J Alzheimers Dis. 2018;62:1141–79.PubMedPubMedCentral
15.
McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson’s disease: prevalence, aetiology and management. Parkinsonism Relat Disord. 2017;35:8–16.PubMed
16.
Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson’s disease: implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2019;104700.
17.
Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000;164(5):1640–3.PubMed
18.
Sakakibara, R, Kishi, M, Ogawa, E, Tateno, F, Uchiyama, T, Yamamoto, T, Yamanishi, T. Bladder, bowel, and sexual dysfunction in Parkinson’s disease. Parkinson’s Disease 2011:1–21.
19.
Gupta A, Rashmi-Krishnan UK, Nageshkumar S, Pal PK, Khanna M, Taly AB. Urinary symptoms in patients with Parkinson’s disease and progressive supranuclear palsy: urodynamic findings and management of bladder dysfunction. Ann Indian Acad Neurol. 2019;22(4):432–6.PubMedPubMedCentral
20.
Savard E, Declemy A, Coindreau V, Babany F, Chesnel C, Charlanes A, et al. Self-intermittent-catheterization and urinary retention in Parkinsonian syndromes. Prog Urol. 2018;28(17):987–92.PubMed
21.
Godmer M, Guinet-Lacoste A, Charvier K, Luauté J, Rode G, Soler JM, et al. Is there any obstruction other than prostatic obstruction in idiopathic Parkinson’s disease? Prog Urol. 2019;29(11):579–85.PubMed
22.
Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson’s disease. J Urol. 1983;129(1):80–3.PubMed
23.
24.
Stoffel JT. Chronic urinary retention in multiple sclerosis patients: physiology, systematic review of urodynamic data, and recommendations for care. Urol Clin North Am. 2017;44:429–39.PubMed
25.
Lemack GE, Frohman E, Ramnarayan P. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. Urology. 2007;69:893–7.PubMed
26.
Jazayeri SB, Ataeepour M, Rabiee H, Motevalian SA, Saadat S, Vaccaro AR, et al. Prevalence of spinal cord injury in Iran: a 3-source capture-recapture study. Neuroepidemiology. 2015;45:28–33.PubMed
27.
Taweel WA, Seyam R. Neurogenic bladder in spinal cord injury patients. Res Reports Urol. 2015;7:85–99.
28.
Sivkov AV, Romikh VV, Egorov AA. Use of alpha1-adrenergic blockaders in voiding disorders in women. Urologiia. 2002;5:52–63.
29.
Kilicarslan H, Ayan S, Vuruskan H, Gokce G, Gultekin EY. Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin. Int Urol Nephrol. 2006;38:537–41.PubMed
30.
Medical Advisory Secretariat. Intrathecal baclofen pump for spasticity: an evidence-based analysis. Ontario Health Technology Assessment Series. 2005:5(7).
31.
Del Fabro AS, Mejia M, Nemunaitis G. An investigation of the relationship between autonomic dysreflexia and intrathecal baclofen in patients with spinal cord injury. J Spinal Cord Med. 2018;41(1):102–5.PubMed
32.
Lloyd LK, Kuhlemeier KV, Fine PR, et al. Initial bladder management in spinal cord injury: does it make a difference? J. Urol. 1986;135:523–7.PubMed
33.
Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 1972;107:458–61.PubMed
34.
Lamin E, Newman DK. Clean intermittent catheterization revisited. Int Urol Nephrol. 2016;48:931–9.PubMed
35.
Chartier-Kastler E, Denys P. Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retention. Neurourol Urodyn. 2011;30:21–31.PubMed
36.
37.
Virseda-Chamorro M, Salinas-Casado J, Rubio-Hidalgo E, et al. Risk factors of urethral diverticula in male patients with spinal cord injury. Spinal Cord. 2015;53(11):803–6.PubMed
38.
Stern JA, Clemens JQ. Osteomyelitis of the pubis: a complication of a chronic indwelling catheter. Urology. 2003;61(2):462.PubMed
39.
McGuire EJ, Savastano J. Comparative urological outcome in women with spinal cord injury. J Urol. 1986;135:730–1.PubMed
40.
Bennett CJ, Young MN, Adkins RH, Diaz F. Comparison of bladder management complication outcomes in female spinal cord injury patients. J Urol. 1995;153:1458–60.PubMed
41.
Larsen LD, Chamberlin DA, Khonsari F, Ahlering TA. Retrospective analysis of urologic complications in male patients with spinal cord injury managed with and without indwelling urinary catheters. Urology. 1997;50:418–22.PubMed
42.
Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163:768–72.PubMed
43.
Katsumi HK, Kalisvaart JF, Ronningen LD, Hovey RM. Urethral versus suprapubic catheter: choosing the best bladder management for male spinal cord injury patients with indwelling catheters. Spinal Cord. 2010;48:325–9.PubMed
44.
Mitsui T, Minami K, Furuno T, Morita H, Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics?. A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol. 2000;38(4):434–8.PubMed
45.
Gui-Zhong L, Li-Bo M. Bladder cancer in individuals with spinal cord injuries: a meta-analysis. Spinal Cord. 2017;55(4):341–5.PubMed
46.
Ismail S, Karsenty G, Chartier-Kastler E, Cussenot O, Compérat E, Rouprêt M, et al. Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourol Urodyn. 2018;37:1386–95.PubMed
47.
Perrouin-Verbe B, Labat JJ, Richard I, Mauduyt de la Greve I, Buzelin JM, Mathe JF. Clean intermittent catheterisation from the acute period in spinal cord injury patients. Long term evaluation of urethral and genital tolerance. Paraplegia. 1995;33:619–24.PubMed
48.
Wyndaele JJ, Maes D. Clean intermittent self-catheterization: a 12-year follow-up. J Urol. 1990;143:906–8.PubMed
49.
Perkash I, Giroux J. Clean intermittent catheterization in spinal cord injury patients: a follow-up study. J Urol. 1993;149:1068–71.PubMed
50.
Moore KN, Fader M, Getliffe K. Long term bladder management by intermittent catheterisation in children and adults. Cochrane Database Syst Rev. 2007;4:CD006008.
51.
Taskinen S, Fagerholm R, Ruutu M. Patient experience with hydrophilic catheters used in clean intermittent catheterization. J Pediatr Urol. 2008;4:367–71.PubMed
52.
Stensballe J, Loom D, Nielsen PN, Tvede M. Hydrophilic-coated catheters for intermittent catheterisation reduce urethral microtrauma: a prospective, randomised, participant-blinded, crossover study of three different types of catheters. Eur Urol. 2005;48:978–83.PubMed
53.
Hedlund H, Hjelmas K, Jonsson O, et al. Hydrophilic versus non-coated catheters for catheterization. Scand J Urol Nephrol. 2001;35:49–53.PubMed
54.
Vapnek JM, Maynard FM, Kim J. A prospective randomized trial of the Lofric hydrophilic coated catheter versus conventional plastic catheter for clean intermittent catheterization. J Urol. 2003;169:994–8.PubMed
55.
Cardenas DD, Moore KN, Dannels-McClure A, Scelza WM, Graves DE, Brooks M, et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial. PM&R. 2011;3:408–17.
56.
Li L, Ye W, Ruan H, Yang B, Zhang S, Li L. Impact of hydrophilic catheters on urinary tract infections in people with spinal cord injury: systematic review and meta-analysis of randomized controlled trials. Arch Phys Med Rehabil. 2013;94:782–7.PubMed
57.
• Calisto FCFS, Vilar FO, Lustosa ES. et al. A new bladder-emptying method in females with neurogenic bladder: a randomized, phase II trial. Neurourol. Urodyn. 2019:38:1721–1727. Six-month outcomes of randomized control trial of intra-urethral self-retaining device against CIC in female NLUTD patients.
58.
Gor RA, Elliott SP. Surgical management of neurogenic lower urinary tract dysfunction. Urol Clin North Am. 2017;44:475–90.PubMed
59.
Ross JC, Gibbon NOK, Damanski M. Division of the external urethral sphincter in the treatment of paraplegic bladder. A preliminary report on a new procedure. Brit J Urol. 1958;30:204–12.PubMed
60.
Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139:919–22.PubMed
61.
Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24–6.PubMed
62.
Utomo E, Groen J and Blok BFM: Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev 2014.
63.
Mehta S, Hill D, Foley N, Hsieh J, Ethans K, Potter P, et al. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil. 2012;93:597–603.PubMed
64.
Kuo HC. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn. 2008;27:793–6.PubMed
65.
Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003;170:1908–12.PubMed
66.
Chen YH, Kuo HC. Botulinum A toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol Int. 2004;73(2):156–62.PubMed
67.
• Jiang YH, Chen SF, Jhang JF, et al. Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. Neurourol. Urodyn. 2018;37:2651–7 A retrospective study of Botox for neurogenic sphincter dysfunction with focus on patient-reported outcomes and uroflowmetry.PubMed
68.
de Sèze M, Petit H, Gallien P, de Sèze MP, Joseph PA, Mazaux JM, et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002;42(1):56–62.PubMed
69.
Gallien P. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670–6.PubMedPubMedCentral
70.
Hu M, Lai S, Zhang Y, Liu M, Wang J. Sacral neuromodulation for lower urinary tract dysfunction in spinal cord injury: a systematic review and meta-analysis. Urol Int. 2019;103:337–43.PubMed
71.
Goldman HB, Lloyd JC, Noblett KL, Carey MP, Castaño Botero JC, Gajewski JB, et al. International Continence Society best practice statement for use of sacral neuromodulation. Neurourol Urodyn. 2018;37:1823–48.PubMed
72.
Yang CC. Bladder management in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):673–86.PubMed
73.
Aharony SM, Lam O, Corcos J. Treatment of lower urinary tract symptoms in multiple sclerosis patients: review of the literature and current guidelines. Can Urol Assoc J. 2017;11(3–4):110–E115.
74.
Levy ME, Elliott SP. Reconstructive techniques for creation of catheterizable channels: tunneled and nipple valve channels. Transl Androl Urol. 2016;5:136–44.PubMedPubMedCentral
75.
Kalkan S, Jaffe WI, Simma-Chiang V, Li ESW, Blaivas JG. Long term results of augmentation cystoplasty and urinary diversion in multiple sclerosis. Can J Urol. 2019;26(3):9774–80.PubMed
76.
Szymanski KM, et al. Additional surgeries after bladder augmentation in patients with spina bifida in the 21st century. J Urol. 2020;203:1–7.
77.
Zachoval R, Pitha J, Medova E, Heracek J, Lukes M, Zalesky M, et al. Augmentation cystoplasty in patients with multiple sclerosis. Urol Int. 2003;70(1):21–6.PubMed
78.
Vian E, Soustelle L, Viale S, Costa P. A technique of continent vesicostomy with ileocystoplasty: study of 32 patients. Prog Urol. 2009;19(2):116–21.PubMed
79.
• Husmann DA, Viers BR. Neurogenic bladder: management of the severely impaired patient with complete urethral destruction: ileovesicostomy, suprapubic tube drainage or urinary diversion – is one treatment modality better than another? Translational Andrology and Urology. 2020;9(1):132–41 This paper reviews NLUTD patients managed with BNC with ileovesicostomy, BNC with SPT, or cystectomy with enteric conduit diversion and finds ileovesicostomy is associated with a significantly increased incidence of urosepsis and late surgical complications.PubMedPubMedCentral
80.
• Myers JB, et al. Patient reported bladder related symptoms and quality of life after spinal cord injury with different bladder management strategies. J. Urol. 2019;202:574–84 This study in SCI patients measured quality of life with different bladder management strategies including surgery.PubMed
81.
Akakpo W, Chartier-Kastler E, Joussain C, Denys P, Lubetzki C, Phé V. Outcomes of ileal conduit urinary diversion in patients with multiple sclerosis. Neurourol Urodyn. 2020:1–7.
82.
Ventimiglia B, Morana C, Lopes M, Lopes L, Savoca F, Consoli C, et al. Disorders of micturition in neurological patients. A clinical study of 786 patients. J Neuro. 1998;245(3):173–7.
83.
Koyanagi T, Morita H, Taniguchi K, Kubota M, Shinno Y, Takamatsu T. Neurogenic urethra: clinical relevance of isolated neuropathic dysfunction of the urethra, and the denervation supersensitivity of the urethra revisited. Eur Urol. 1988;15:77–83.PubMed
84.
Blaivas JG, and Chancellor MB: Cauda equina and pelvic plexus injury. In Chancellor MB, and Blaivas JG (eds): Practical neurourology. Boston: Butterworth-Heinemann 1995:155–164.
85.
McGuire, EJ: Clinical evaluation and treatment of neurogenic vesical dysfunction. In Leslie JA (eds): International perspectives in urology. Williams & Wilkins Baltimore 1984: 43–56.
86.
Cibula D, Sláma J, Velechovská P, Fischerova D, Zikán M, Pinkavová I, et al. Factors affecting spontaneous voiding recovery after radical hysterectomy. Int J Gynecol Cancer. 2010;20:685–90.PubMed
87.
Cheung F, Sandhu JS. Voiding dysfunction after non-urologic pelvic surgery. Curr Urol Rep. 2018;19:1–6.
88.
Derks M, Van Der Velden J, Frijstein MM, Vermeer WM, Stiggelbout AM, Roovers JPWR, et al. Long-term pelvic floor function and quality of life after radical surgery for cervical cancer. Int J Gynecol Cancer. 2016;26:1538–43.PubMed
89.
Raspagliesi F, Bogani G, Spinillo A, Ditto A, Bogliolo S, Casarin J, et al. Introducing nerve-sparing approach during minimally invasive radical hysterectomy for locally-advanced cervical cancer: a multi-institutional experience. Eur J Surg Oncol. 2017;43:2150–6.PubMed
90.
Sun X-L,Wang H-B,Wang Z-Q,Cao T, Yang X, Han JS, Wu YF, Reilly KH, Wang JL Effect of transcutaneous electrical stimulation treatment on lower urinary tract symptoms after class III radical hysterectomy in cervical cancer patients: study protocol for a multicentre, randomized controlled trial. BMC Cancer; 2017:17:416.
91.
Daniels IR, Woodward S, Taylor FG, Raja A, Toomey P. Female urogenital dysfunction following total mesorectal excision for rectal cancer. World J Surg Oncol. 2006;4:6.PubMedPubMedCentral
92.
Kyo K, Sameshima S, Takahashi M, Furugori T, Sawada T. Impact of autonomic nerve preservation and lateral node dissection on male urogenital function after total mesorectal excision for lower rectal cancer. World J Surg. 2006;30:1014–9.PubMed
93.
Lange MM, Van De Velde CJH. Urinary and sexual dysfunction after rectal cancer treatment. Nat Rev Urol. 2011;8:51–7.PubMed
94.
Lange MM, Maas CP, Marijnen CAM, Wiggers T, Rutten HJ, Kranenbarg EK, et al. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg. 2008;95:1020–8.PubMed
95.
Grise P, Thurman S. Urinary incontinence following treatment of localized prostate cancer. Cancer Control. 2001;8:532–9.PubMed
96.
Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1257–80.PubMed
97.
Sterk P, Shekarriz B, Günter S, Nolde J, Keller R, Bruch HP, et al. Voiding and sexual dysfunction after deep rectal resection and total mesorectal excision: prospective study on 52 patients. Int J Color Dis. 2005;20:423–7.
98.
Miyazato M, Kadekawa K, Kitta T, Wada N, Shimizu N, de Groat WC, et al. New frontiers of basic science research in neurogenic lower urinary tract dysfunction. Urol Clin N Am. 2017;44(3):491–505.
99.
Miyazato M, Ashikari A. Therapeutic new targets for stress urinary incontinence in the central nervous system. Japanese Pharmacology Journal. 2020;155(1):16–9.
100.
Verhoef M, Lurvink M, Barf HA, Post MWM, van Asbeck FWA, Gooskens RHJM, et al. High prevalence of incontinence among young adults with spina bifida: description, prediction and problem perception. Spinal Cord. 2005;43:331–40.PubMed
101.
Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg. 2001;34:114–20.PubMed
102.
Bomalaski MD, Teague JL, Brooks B. The long-term impact of urological management on the quality of life of children with spina bifida. J Urol. 1995;154:778–81.PubMed
103.
Malone PS, Wheeler RA, Williams JE. Continence in patients with spina bifida: long term results. Arch Dis Child. 1994;70:107–10.PubMedPubMedCentral
104.
Cameron AP, Wallner LP, Tate DG, Sarma AV, Rodriguez GM, Clemens JQ. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184:213–7.PubMed
105.
Li H, Westney OL. Injection of urethral bulking agents. Urol Clin N Am. 2019;46(1):1–15.
106.
Maggiore LR, et al. Urethral bulking agents versus other surgical procedures for the treatment of female stress urinary incontinence: a systematic review and meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2015;189:48–54.
107.
El-Azab AS, El-Nashar SA. Midurethral slings versus the standard pubovaginal slings for women with neurogenic stress urinary incontinence. Int. Urogynecol. J Pelvic Floor Dysfunct. 2014;26:427–32.
108.
Hamid R, Khastgir J, Arya M, Patel HRH, Shah PJR. Experience of tension-free vaginal tape for the treatment of stress incontinence in females with neuropathic bladders. Spinal Cord. 2003;41:118–21.PubMed
109.
Abdul-Rahman A, Attar KH, Hamid R, Shah PJR. Long-term outcome of tension-free vaginal tape for treating stress incontinence in women with neuropathic bladders. BJU Int. 2010;106:827–30.PubMed
110.
Mcguire EJ, Lytton B. Pubovaginal sling procedure for stress incontinence. J Urol. 1978;119(1):82–4.PubMed
111.
•• Phe V, Léon P, Granger B, et al. Stress urinary incontinence in female neurological patients: long-term functional outcomes after artificial urinary sphincter (AMS 800TM) implantation. Neurourol Urodyn. 2017;36(3):764–9 Long-term AUS outcomes specifically on ISD in female patients with NLUTD.PubMed
112.
Stoffel JT, McGuire EJ. Outcome of urethral closure in patients with neurologic impairment and complete urethral destruction. Neurourol Urodyn. 2006;25:19–22.PubMed
113.
Ginger VA. Bladder neck closure and suprapubic tube placement in a debilitated patient population. Neurourol Urodyn. 2010;29:382–6.PubMed
114.
Shpall AI, Ginsberg DA. Bladder neck closure with lower urinary tract reconstruction: technique and long-term follow-up. J Urol. 2004;172:2296–9.PubMed
115.
Willis H, Safiano NA, Lloyd LK. Comparison of transvaginal and retropubic bladder neck closure with suprapubic catheter in women. J Urol. 2015;193:196–202.PubMed
116.
Hou J, Bacsu C, Zimmern PE, et al. 1422 bladder neck closure in women: lessons learned from a tertiary neurogenic bladder clinic. J Urol. 2013;189:e582.
117.
Altaweel WM, Rajih E, Alkhudair W. Interposition flaps in vesicovaginal fistula repairs can optimize cure rate. Urol Ann. 2013;5(4):270–2.PubMedPubMedCentral
118.
Evans DH, Madjar S, Politano VA, Bejany DE, Lynne CM, Gousse AE. Interposition flaps in transabdominal vesicovaginal fistula repairs: are they really necessary? Urology. 2001;57:670–4.PubMed
119.
Delong J, Tighiouart H, Stoffel J. Urinary diversion/reconstruction for cases of catheter intolerant secondary progressive multiple sclerosis with refractory urinary symptoms. J Urol. 2011;185:2201–6.PubMed
Metadaten
Titel
Addressing Sphincter Dysfunction in the Female with Neurogenic Lower Urinary Tract Dysfunction
verfasst von
Javier E. Santiago
Anne P. Cameron
Roberto A. Navarrete
Publikationsdatum
03.08.2020
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 3/2020
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-020-00597-x

Weitere Artikel der Ausgabe 3/2020

The Role of Urodynamic Testing Prior to Third-Line OAB Therapy

  • Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Phenotypes of BPS/IC

  • Open Access
  • BPS/Interstitial Cystitis (D Castro-Diaz and Y Igawa, Section Editors)

Current State of Fetal Intervention for Obstructive Uropathy–Focus on Bladder

  • Pediatric Bladder Dysfunction (J Thomas and D Clayton, Section Editors)

Optimizing Neuromodulation Testing—Who, When, and How?

  • Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

Benefits of an International Volunteer Experience in Residency Training

  • Global Health (K McCammon, Section Editor)

Complementary and Alternative Medicine for the Management of Interstitial Cystitis/Bladder Pain Syndrome: a Recent Update

  • BPS/Interstitial Cystitis (D Castro-Diaz and Y Igawa, Section Editors)

Neu im Fachgebiet Urologie

Hohe Atrophierate nach Hodentorsion im Kindesalter

Auf längere Sicht ist die Atrophierate nach einer Hodentorsion pädiatrischer Patienten erschreckend hoch. Das hat eine Studie mit jahrelanger Nachbeobachtung ergeben. Entscheidend ist die Zeit, die bis zur Detorsion verstreicht.

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

"Die Erektionsstörung ist keine isolierte Erkrankung"

Werden Erektionsstörungen gut behandelt (und das ist möglich), steigt die Lebensqualität enorm. Tipps für eine gute Kommunikation mit den Patienten gibt Androloge Dr. med. Jann-Frederik Cremers in dieser Folge. Welche Fragen sollten gestellt und an welche Ursachen gedacht werden? Und was ist zu tun, wenn PDE-5-Hemmer und Lebensstilveränderungen nicht ausreichend wirken?

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise